Literature DB >> 15914528

Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly.

M Filopanti1, C Ronchi, E Ballarè, S Bondioni, A G Lania, M Losa, S Gelmini, A Peri, C Orlando, P Beck-Peccoz, A Spada.   

Abstract

OBJECTIVE: The aim of the study was to investigate the possible correlation of single nucleotide polymorphisms in somatostatin receptor (SSTR)2 and SSTR5 genes with the responsiveness to somatostatin analogs in a cohort of acromegalic patients. STUDY
DESIGN: Three single nucleotide polymorphisms (a-83 g, c-57 g, and t80c) of SSTR2 and three (t-461c, c325t, and c1004t) of SSTR5 were analyzed in 66 acromegalic patients with different responsiveness to somatostatin analogs and 66 healthy controls.
RESULTS: Allele frequencies in patients and controls were similar. No association between SSTR2 genotypes and GH and IGF-I levels was found. When considering SSTR5 variants, patients homozygous or heterozygous for the substitution c1004 (P+) showed basal IGF-I levels significantly lower than patients homozygous for 1004t (P-). Moreover, serum GH levels were lower in patients with P+/T- haplotype (having c1004 allele and no t-461 allele) than in those with P-/T+. No correlation between SSTR2 and SSTR5 genotypes, responsiveness to somatostatin therapy, and mRNA expression in the removed adenomas (n = 10) was found.
CONCLUSIONS: These data suggest a role for SSTR5 t-461c and c1004t alleles in influencing GH and IGF-I levels in patients with acromegaly, whereas SSTR2 and SSTR5 variants seem to have a minor role in determining the responsiveness to somatostatin analogs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914528     DOI: 10.1210/jc.2005-0132

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.

Authors:  Erika Peverelli; Andrea G Lania; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

Review 2.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

3.  Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.

Authors:  Fangyi Gu; Fredrick R Schumacher; Federico Canzian; Naomi E Allen; Demetrius Albanes; Christine D Berg; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Julie E Buring; Nathalie Chabbert-Buffet; Stephen J Chanock; Françoise Clavel-Chapelon; Vanessa Dumeaux; J Michael Gaziano; Edward L Giovannucci; Christopher A Haiman; Susan E Hankinson; Richard B Hayes; Brian E Henderson; David J Hunter; Robert N Hoover; Mattias Johansson; Timothy J Key; Kay-Tee Khaw; Laurence N Kolonel; Pagona Lagiou; I-Min Lee; Loic LeMarchand; Eiliv Lund; Jing Ma; N Charlotte Onland-Moret; Kim Overvad; Laudina Rodriguez; Carlotta Sacerdote; Maria-José Sánchez; Meir J Stampfer; Pär Stattin; Daniel O Stram; Gilles Thomas; Michael J Thun; Anne Tjønneland; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Walter C Willett; Meredith Yeager; Shumin M Zhang; Rudolf Kaaks; Elio Riboli; Regina G Ziegler; Peter Kraft
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-01       Impact factor: 4.254

4.  Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation.

Authors:  Luis V Syro; Jamie L Sundsbak; Bernd W Scheithauer; Rodrigo A Toledo; Mauricio Camargo; Christina M Heyer; Tomoko Sekiya; Humberto Uribe; Jorge I Escobar; Martin Vasquez; Fabio Rotondo; Sergio P A Toledo; Kalman Kovacs; Eva Horvath; Dusica Babovic-Vuksanovic; Peter C Harris
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 5.  Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Ning-Ai Liu; Shlomo Melmed
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.

Authors:  Donghui Li; Motofumi Tanaka; F Charles Brunicardi; William E Fisher; Richard A Gibbs; Marie-Claude Gingras
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

Review 7.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

8.  Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly.

Authors:  Darja Ciganoka; Inga Balcere; Ivo Kapa; Raitis Peculis; Andra Valtere; Liene Nikitina-Zake; Ieva Lase; Helgi B Schiöth; Valdis Pirags; Janis Klovins
Journal:  Eur J Endocrinol       Date:  2011-08-02       Impact factor: 6.664

Review 9.  Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement.

Authors:  Erika Peverelli; Donatella Treppiedi; Elena Giardino; Eleonora Vitali; Andrea G Lania; Giovanna Mantovani
Journal:  Front Endocrinol (Lausanne)       Date:  2015-12-22       Impact factor: 5.555

10.  FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.

Authors:  Shereen Ezzat; Ri Wang; Melania Pintilie; Sylvia L Asa
Journal:  Oncotarget       Date:  2017-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.